Utility of uroplakin II expression as a marker of urothelial carcinoma
Utility of uroplakin II expression as a marker of urothelial carcinoma
复制标题
DOI：
10.1016/j.humpath.2014.09.007
复制
发表时间：
2015-01-01
期刊：
影响因子：
3.3
通讯作者：
Netto, George J.
中科院分区：
文献类型：
--
作者：
Tian, Wei;Guner, Gunes;Netto, George J.
尿斑蛋白是终末分化型尿路上皮的标志物。尿斑蛋白（Uroplakin，UPII）是一种新发现的尿路上皮癌（UC）的敏感标志物。UPII在不同类型UC中的表达谱及其在诊断环境中的效用是需要的。我们评估了膀胱组织微阵列中UPII的表达，包括低恶性潜能的尿路上皮肿瘤（n = 8）、低级别乳头状UC（n = 72）、非侵袭性高级别乳头状UC（n = 77）、原位UC（n = 27）和侵袭性高级别UC（INVUC）（n = 122）。还评估了52例乳腺癌和38例高级别前列腺癌中的UPII表达。将UPII表达与加塔结合蛋白3（GATA 3）和雌激素受体进行比较，以探讨其在上述3种恶性肿瘤鉴别诊断中的作用。在83.0%的UC中观察到UPII标记，包括95.7%的非侵袭性UC和65.6%的INVUC。UPII标记未发现在任何乳腺癌和前列腺癌。GATA 3阳性率为91.6%，其中非侵袭性UC为96.4%，INVUC为85.1%，其强度和范围均强于UPII（P
Uroplakins are markers of terminally differentiated urothelium. Uroplakin (UPII) is a newly described sensitive marker for urothelial carcinoma (UC). The expression profile of UPII in different types of UC and its utility in the diagnostic setting are needed. We evaluated UPII expression in bladder tissue microarrays, including urothelial neoplasm of low malignant potential (n = 8), low-grade papillary UC (n = 72), noninvasive high-grade papillary UC (n = 77), UC in situ (n = 27), and invasive high-grade UC (INVUC) (n = 122). UPII expression in 52 breast carcinomas and 38 high-grade prostate adenocarcinomas was also assessed. UPII expression was compared with GATA binding protein 3 (GATA3) and estrogen receptor for its role in facilitating the differential diagnosis of the above 3 types of malignancy. UPII labeling was seen in 83.0% of UC overall, including 95.7% of noninvasive UC and 65.6% of INVUC. UPII labeling was not found in any breast and prostate carcinomas. In comparison, GATA3 labeling was seen in 91.6% of all UCs, including 96.4% of noninvasive UCs and 85.1% of INVUC, with stronger intensity and extent compared with UPII (P